Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

722
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
722
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

783
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
783
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

836
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
836
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.0K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.0K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

789
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
789

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in prevalence of type 2 diabetes, obesity and hypertension in urban India since 2000: A Systematic review and meta-analysis.

Epidemiologic reviews·2026
Same author

Reply to H Pu.

The American journal of clinical nutrition·2026
Same author

Physical Activity Does Not Fully Offset the Health Risks of Sedentary Behaviour.

Medicine and science in sports and exercise·2026
Same author

Physical Activity Does Not Fully Offset the Health Risks of Sedentary Behaviour: Response to Ekelund and Colleagues.

Medicine and science in sports and exercise·2026
Same author

Multidimensional effects of personalized exercise intervention in type 2 diabetes: a randomized controlled trial.

Science bulletin·2026
Same author

Is it time to integrate the 24-hour movement paradigm into metabolic and bariatric surgery practice and research? A call to action.

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery·2026

Related Experiment Video

Updated: Mar 10, 2026

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

13.3K

Adding exercise or subtracting sitting time for glycaemic control: where do we stand?

Paddy C Dempsey1,2, Megan S Grace3,4,5, David W Dunstan3,4,6,7,8

  • 1Baker IDI Heart and Diabetes Institute, Level 4, 99 Commercial Rd, Melbourne, VIC, 3004, Australia. paddy.dempsey@bakeridi.edu.au.

Diabetologia
|December 14, 2016
PubMed
Summary

Reducing sitting time with standing and light activity may improve glycaemic control in type 2 diabetes patients. This offers an alternative to structured exercise, addressing low adherence to guidelines.

Keywords:
CardiometabolicCardiovascularContinuous glucose monitorDiabetesEnergy expenditureExerciseGlycaemic controlLipidsObjectivePatternsPhysical activityPublic healthSedentarySitting

More Related Videos

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.8K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.1K

Related Experiment Videos

Last Updated: Mar 10, 2026

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

13.3K
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.8K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.1K

Area of Science:

  • Endocrinology
  • Metabolic Health
  • Exercise Physiology

Background:

  • Type 2 diabetes management often relies on structured exercise, but adherence is low.
  • Sedentary environments and prolonged sitting are prevalent and detrimental to glycaemic control.
  • Emerging evidence suggests reducing and interrupting sitting time can improve metabolic health.

Discussion:

  • Duvivier et al. present findings on reducing sitting time for type 2 diabetes patients.
  • This strategy, involving standing and light activity, may be a viable alternative to traditional exercise.
  • The study highlights the importance of considering the entire physical activity spectrum.

Key Insights:

  • Reducing and breaking up sitting time shows promise for improving glycaemic control.
  • Light-intensity activities and standing interventions can positively impact metabolic markers.
  • This approach offers a more accessible strategy for individuals with type 2 diabetes.

Outlook:

  • Further research is needed to explore optimal durations and intensities of reduced sitting time.
  • Clinical implementation could involve integrating standing breaks and light activity into daily routines.
  • Future studies should investigate long-term effects and patient adherence to these interventions.